{
    "N/R/U": null,
    "Applicant": "Novo Nordisk Inc.",
    "BLA Number": "203314",
    "Proprietary Name": "Tresiba",
    "Proper Name": "insulin degludec",
    "BLA Type": "351(a)",
    "Strength": "1,000UNITS/10ML (100UNITS/ML)",
    "Dosage Form": "Injection ",
    "Route of Administration": "Subcutaneous",
    "Product Presentation": "Multi-Dose Vial",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "21-Nov-18",
    "Ref. Product Proper Name": null,
    "Ref. Product Proprietary Name": null,
    "Supplement Number": "10",
    "Submission Type": "Supplement",
    "License Number": "1261",
    "Product Number": "3",
    "Center": "CDER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": null
}